Adc Therapeutics Ltd Stock News

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical g

With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

January's payrolls report shows 353,000 jobs

ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.

The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.

ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted

ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the r

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.65 per share a year ago.

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m.

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in S